# Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

> **NCT04521413** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Treadwell Therapeutics, Inc** · enrollment: 170 (estimated)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** CFI-402411
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04521413
- **Lead sponsor:** Treadwell Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-31
- **Primary completion:** 2025-11
- **Final completion:** 2025-12
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521413, "Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04521413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*